[Substitution therapy with prothrombin complex concentrates in acquired coagulation disorders].
Over the past 11 years two different plasma concentrates--Prothromblex500 (factor II, IX and X) and Prothromblex Total500 (factor II, VII, IX and X) have been used in the treatment of 246 patients with acquired coagulation disorders, in particular deficiencies of the prothrombin complex (factor II, VII, IX and X). Patients on oral anticoagulation or suffering from liver disease required substitute therapy for severe bleeding episodes, acute operations or invasive diagnostic procedures. Serial coagulation studies and analyses showed that both concentrates achieved adequate correlation of the abnormal coagulation, whereby better results were obtained in patients on oral anticoagulation than in patients with severe liver disease. All operations and diagnostic procedures were completed without haemorrhagic complications, whilst the patients admitted for a severe bleeding episode were rapidly brought under control. These plasma concentrates did not cause any side effects. No case of intravascular coagulation was observed following substitution therapy.
D000925:Anticoagulants / Q000009:adverse effects; D001778:Blood Coagulation Disorders / Q000209:etiology / Q000628:therapy*; D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D004338:Drug Combinations; D005164:Factor IX / Q000627:therapeutic use; D005167:Factor VII / Q000627:therapeutic use; D005170:Factor X / Q000627:therapeutic use; D006801:Humans; D008107:Liver Diseases / Q000150:complications; D011183:Postoperative Complications; D011516:Prothrombin / Q000627:therapeutic use
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D004338:Drug Combinations; D005167:Factor VII; D011516:Prothrombin; D005164:Factor IX; D005170:Factor X
Substitutionstherapie mit Konzentraten des Prothrombinkomplexes bei erworbenen Gerinnungsstörungen.